ILTS Insights – Immunology and the allograft revisited?
Webinar
ILTS Insights: Immunology and the allograft revisited?
Date: February 24, 2022
Time: 1:00 PM CET / 7:00 AM EST
Understanding rejection mechanisms and subsequently improving immunosuppression strategies after liver transplantation is still a goal for transplant specialists. All the efforts aim to find a balance between efficacy in preventing rejection and safety with the minimization of side effects. While the use of standard protocols is an easy choice, there is a growing interest in a more complex, personalized approach. This webinar will focus on alloreactive T lymphocytes which are the primary mediators of rejection, early and long-term immunosuppression regimens, discussing different approaches and perspectives for future research.
Objectives:
- Learn how to track donor-reactive T cells
- Discuss the use of induction therapy, indication, benefits and side effects
- Discuss immunosuppression minimization and the use of mTOR inhibitors
Agenda:
- Introduction
- Tracking the alloresponse in human transplant recipients (Megan Sykes)
- Is induction therapy justified in all LT recipients? (Varuna Aluvihare)
- CNI reduced exposure/withdrawal in maintenance therapy: the role of mTOR inhibitors (Faouzi Saliba)
- Q&A moderated by Geoffrey McCaughan and Eleonora De Martin
Speakers
Moderators
Dr McCaughan is currently the AW Morrow Professor of Medicine (Gastroenterology and Hepatology) at the Royal Prince Alfred Hospital and the University of Sydney. He is also Director of Transplant Hepatology, the GE/Liver Diagnostic Laboratory, and the Liver Immunobiology Research Laboratory Centenary Research Institute for Cancer and Cell Biology. His primary clinical interests are liver transplantation, viral hepatitis and autoimmune hepatitis. |
|
Dr De Martin is a transplant hepatologist at Centre Hépato-Biliaire, Paul Brousse Hospital in France. She is the Vice-Chair of ILTS Vanguard Committee and topic coordinator of the ILTS Liver Transplant Immunology Special Interest Group. Her fields of interest include liver transplantation, autoimmune hepatitis in particular severe acute and fulminant forms and hepatic toxicity of immunotherapy for metastatic cancer. |